Recall Enforment Report D-0205-2024

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by Legacy Pharmaceutical Packaging LLC, originally initiated on 12-11-2023 for the product Sertraline Tablets, USP 100 mg, 30 tablets per bottle, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, Packaged by: Legacy Pharmaceutical Packaging LLC., Earth City, MO 63045, NDC# 68645-523-54 The product was recalled due to cgmp deviations: inadequate line clearance which may result in a potential comingling of product.. The product was distributed in Ca And Ar and the recall is currently ongoing.

Field Name Field Value
Event ID 93605 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0205-2024 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern CA and AR What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Sertraline Tablets, USP 100 mg, 30 tablets per bottle, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, Packaged by: Legacy Pharmaceutical Packaging LLC., Earth City, MO 63045, NDC# 68645-523-54
Reason For Recall CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product. What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 161,664 bottles Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 01-03-2024
Recall Initiation Date 12-11-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Initial Firm Notification Letter Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Legacy Pharmaceutical Packaging LLC
Code Info Lot #: 222033, exp. date 08/31/2024 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 68645-521-54; 68645-522-54; 68645-523-54
Status Ongoing

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
68645-521Sertraline Hydrochloride Sertraline HydrochlorideTabletOralLegacy Pharmaceutical Packaging, LlcHuman Prescription Drug
68645-522Sertraline Hydrochloride Sertraline HydrochlorideTabletOralLegacy Pharmaceutical Packaging, LlcHuman Prescription Drug
68645-523Sertraline Hydrochloride Sertraline HydrochlorideTabletOralLegacy Pharmaceutical Packaging, LlcHuman Prescription Drug